Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F., Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib, «ANTI-CANCER DRUGS», 2024, 35, pp. 86 - 88 [Scientific article]
Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Giglio A., From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC), «DIAGNOSTICS», 2024, 14, Article number: 48 , pp. 1 - 29 [Scientific article]Open Access
Ricciuti B.; Lamberti G.; Puchala S.R.; Mahadevan N.R.; Lin J.-R.; Alessi J.V.; Chowdhury A.; Li Y.Y.; Wang X.; Spurr L.; Pecci F.; Di Federico A.; Venkatraman D.; Barrichello A.P.; Gandhi M.; Vaz V.R.; Pangilinan A.J.; Haradon D.; Lee E.; Gupta H.; Pfaff K.L.; Welsh E.L.; Nishino M.; Cherniack A.D.; Johnson B.E.; Weirather J.L.; Dryg I.D.; Rodig S.J.; Sholl L.M.; Sorger P.; Santagata S.; Umeton R.; Awad M.M., Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer, «JOURNAL OF CLINICAL ONCOLOGY», 2024, 42, pp. 1311 - 1321 [Scientific article]Open Access
Rossi S.; Costa R.; di Federico A.; Lo Bianco F.; D'Angelo R.; Asioli G.M.; De Giglio A.; Sperandi F.; Guarino M.; Rinaldi R.; Ardizzoni A.; Cenacchi G.; Gelsomino F., Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report, «JOURNAL OF THORACIC ONCOLOGY», 2024, 19, pp. 1352 - 1355 [Scientific article]
Di Federico, A.; Alden, S. L.; Smithy, J. W.; Ricciuti, B.; Alessi, J. V.; Wang, X.; Pecci, F.; Lamberti, G.; Gandhi, M. M.; Vaz, V. R.; Spurr, L. F.; Sholl, L. M.; Pfaff, K. L.; Rodig, S. J.; Li, Y. Y.; Cherniack, A. D.; Nishino, M.; Johnson, B. E.; Awad, M. M., Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer, «ANNALS OF ONCOLOGY», 2024, 35, pp. 1 - 902 [Scientific article]
Sini, C.; Di Federico, A.; Bironzo, P.; De Giglio, A.; Gelsomino, F., Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations, «EUROPEAN JOURNAL OF CANCER», 2024, 213, Article number: 115085 , pp. 1 - 2 [Scientific article]
De Giglio A.; Di Federico A.; Gariazzo E.; Metro G., Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy, «MED», 2024, 5, pp. 1 - 3 [Scientific article]
Favorito V.; Ricciotti I.; De Giglio A.; Fabbri L.; Seminerio R.; Di Federico A.; Gariazzo E.; Costabile S.; Metro G., Non-small cell lung cancer: an update on emerging EGFR-targeted therapies, «EXPERT OPINION ON EMERGING DRUGS», 2024, 29, pp. 139 - 154 [Scientific article]
Wang X.; Lamberti G.; Di Federico A.; Alessi J.; Ferrara R.; Sholl M.L.; Awad M.M.; Vokes N.; Ricciuti B., Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities, «ANNALS OF ONCOLOGY», 2024, 35, pp. 508 - 522 [Scientific article]
De Giglio A.; Deiana C.; Di Federico A., Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients, «JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY», 2023, 149, pp. 1835 - 1847 [Scientific article]Open Access
Thummalapalli R.; Ricciuti B.; Bandlamudi C.; Muldoon D.; Rizvi H.; Elkrief A.; Luo J.; Alessi J.V.; Pecci F.; Lamberti G.; Di Federico A.; Hong L.; Zhang J.; Heymach J.V.; Gibbons D.L.; Plodkowski A.J.; Ravichandran V.; Donoghue M.T.A.; Vanderbilt C.; Ladanyi M.; Rudin C.M.; Kris M.G.; Riely G.J.; Chaft J.E.; Hellmann M.D.; Vokes N.I.; Awad M.M.; Schoenfeld A.J., Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer, «CLINICAL CANCER RESEARCH», 2023, 29, pp. 4408 - 4418 [Scientific article]Open Access
Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A., Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review, «LUNG CANCER: TARGETS AND THERAPY», 2023, 14, pp. 11 - 25 [Scientific article]
Alessi J.V.; Elkrief A.; Ricciuti B.; Wang X.; Cortellini A.; Vaz V.R.; Lamberti G.; Frias R.L.; Venkatraman D.; Fulgenzi C.A.M.; Pecci F.; Recondo G.; Di Federico A.; Barrichello A.; Park H.; Nishino M.; Hambelton G.M.; Egger J.V.; Ladanyi M.; Digumarthy S.; Johnson B.E.; Christiani D.C.; Lin X.; Gainor J.F.; Lin J.J.; Pinato D.J.; Schoenfeld A.J.; Awad M.M., Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC, «JOURNAL OF THORACIC ONCOLOGY», 2023, 18, pp. 731 - 743 [Scientific article]
Scalera S.; Ricciuti B.; Mazzotta M.; Calonaci N.; Alessi J.V.; Cipriani L.; Bon G.; Messina B.; Lamberti G.; Di Federico A.; Pecci F.; Milite S.; Krasniqi E.; Barba M.; Vici P.; Vecchione A.; De Nicola F.; Ciuffreda L.; Goeman F.; Fanciulli M.; Buglioni S.; Pescarmona E.; Sharma B.; Felt K.D.; Lindsay J.; Rodig S.J.; De Maria R.; Caravagna G.; Cappuzzo F.; Ciliberto G.; Awad M.M.; Maugeri-Sacca M., Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma, «ANNALS OF ONCOLOGY», 2023, 34, pp. 275 - 288 [Scientific article]
Elkrief A.; Alessi J.M.V.; Ricciuti B.; Brown S.; Rizvi H.; Preeshagul I.R.; Wang X.; Pecci F.; Di Federico A.; Lamberti G.; Egger J.V.; Chaft J.E.; Rudin C.M.; Riely G.J.; Kris M.G.; Ladanyi M.; Chen Y.; Hellmann M.D.; Shen R.; Awad M.M.; Schoenfeld A.J., Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2023, 11, Article number: e006994 , pp. 1 - 11 [Scientific article]Open Access
